Taipei Exchange - Delayed Quote TWD

G&E Herbal Biotechnology Co., Ltd. (4911.TWO)

Compare
57.90
+1.00
+(1.76%)
At close: 1:30:11 PM GMT+8
Loading Chart for 4911.TWO
DELL
  • Previous Close 56.90
  • Open 56.90
  • Bid 57.80 x --
  • Ask 58.00 x --
  • Day's Range 56.70 - 57.90
  • 52 Week Range 48.58 - 61.70
  • Volume 54,232
  • Avg. Volume 45,327
  • Market Cap (intraday) 3.416B
  • Beta (5Y Monthly) -0.22
  • PE Ratio (TTM) 38.09
  • EPS (TTM) 1.52
  • Earnings Date --
  • Forward Dividend & Yield 0.57 (1.00%)
  • Ex-Dividend Date Aug 20, 2024
  • 1y Target Est --

G&E Herbal Biotechnology Co., Ltd. engages in development and commercialization of novel botanical extraction technology and products. It offers Hepanamin capsules; botoniocal healthcare product, such as SR100, Goji-Ex, arthrenhergy plus, astragali radix, and prosta capsules; botanical anti-aging cosmetic, which includes rejuvenate haute essential set, classic selection set, facial cleansing essence, botonic extract toner, moisturizing cream, and serum, and essential oil; smile cream and topical gel; and adult products, including lubricants. G&E Herbal Biotechnology Co., Ltd. was founded in 2002 and is based in Tainan City, Taiwan.

www.geherbs.com.tw

37

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4911.TWO

View More

Performance Overview: 4911.TWO

Trailing total returns as of 2/7/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

4911.TWO
2.84%
TSEC CAPITALIZATION WEIGHTED ST
1.92%

1-Year Return

4911.TWO
5.15%
TSEC CAPITALIZATION WEIGHTED ST
29.74%

3-Year Return

4911.TWO
119.99%
TSEC CAPITALIZATION WEIGHTED ST
31.16%

5-Year Return

4911.TWO
67.67%
TSEC CAPITALIZATION WEIGHTED ST
102.18%

Compare To: 4911.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4911.TWO

View More

Valuation Measures

As of 2/6/2025
  • Market Cap

    3.36B

  • Enterprise Value

    3.07B

  • Trailing P/E

    37.52

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    14.87

  • Price/Book (mrq)

    4.18

  • Enterprise Value/Revenue

    13.60

  • Enterprise Value/EBITDA

    25.23

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    39.70%

  • Return on Assets (ttm)

    7.09%

  • Return on Equity (ttm)

    11.20%

  • Revenue (ttm)

    211.15M

  • Net Income Avi to Common (ttm)

    83.82M

  • Diluted EPS (ttm)

    1.52

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    324.13M

  • Total Debt/Equity (mrq)

    0.29%

  • Levered Free Cash Flow (ttm)

    113.95M

Research Analysis: 4911.TWO

View More

People Also Watch